Publication:
Prognostic value of pet/ct determined sarcopenia inpatients with resected ampullary carcinoma

Simple item page
dc.contributor.authorÖZGÜVEN, SALİH
dc.contributor.authorARIKAN, RUKİYE
dc.contributor.authorsBAŞOĞLU TÜYLÜ T., ÖZGÜVEN S., ENGÜR C. Ö. , AKAGÜNDÜZ F., DEMİRCAN N. C. , ARIKAN R., TEMİZ F., ŞENGÜN S., IŞIK S., AKIN TELLİ T., et al.
dc.date.accessioned2022-12-19T11:01:50Z
dc.date.available2022-12-19T11:01:50Z
dc.date.issued2022-10-01
dc.description.abstractObjectives: Our aim is to investigate the prognostic value and effect on chemotherapy toxicity of pre-treatment sarcopenia determined with positron emission tomography/computerized tomography(PET/CT) in patients with ampullary carcinoma. Methods: Characteristics of patients retrieved retrospectively. Skeletal muscle area(SMA) measurement of the muscle at L3 vertebra level was evaluated for each patient from their PET/CT scan taken at the time of diagnosis. The sex-specific cut-off levels for determining sarcopenia were <38.5 cm2/m2 for females and <52.4 cm2/m2 for males. Association between oncological and radiological data was analyzed. Results: A total of 90 patients included in the study. Median age at diagnosis was 62(range: 44-77). Half of the patients were sarcopenic. Pre-treatment sarcopenia was determined as an independent variable predicting survival for both disease-free-survival(DFS) and overall survival(OS). Sarcopenic patients had statistically significant shorter OS(67.2 months for non-sarcopenic patients vs 53.2 months for sarcopenic patients, 95%CI:63.6-70.9, p<0.001), and a trend for shorter DFS(48 months for non-sarcopenic patients vs 36.8 months for sarcopenic patients, 95%CI:20.3-53.4, p=0.95) was also determined. On the other hand, chemotherapy related toxicity has also seen more in sarcopenic patients. Conclusion: Detecting the presence of pre-treatment sarcopenia may enable clinicians to predict the patient group with low survival and high probability of treatment toxicity. In order to protect this group of patients from toxicity, pretreatment sarcopenia measurement should be applied in routine practice and should guide treatment plan.
dc.identifier.citationBAŞOĞLU TÜYLÜ T., ÖZGÜVEN S., ENGÜR C. Ö. , AKAGÜNDÜZ F., DEMİRCAN N. C. , ARIKAN R., TEMİZ F., ŞENGÜN S., IŞIK S., AKIN TELLİ T., et al., "Prognostic Value Of PET/CT Determined Sarcopenia in Patients with Resected Ampullary Carcinoma", Eurasian Journal of Medical Investigation, cilt.7, sa.1, ss.32-41, 2022
dc.identifier.doi10.14744/ejmi.2023.28845
dc.identifier.endpage41
dc.identifier.issn2602-3164
dc.identifier.issue1
dc.identifier.startpage32
dc.identifier.urihttps://hdl.handle.net/11424/283708
dc.identifier.volume7
dc.language.isoeng
dc.relation.ispartofEurasian Journal of Medical Investigation
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAmpullary carcinoma
dc.subjectsarcopenia
dc.subjecttoxicity
dc.subjectsurvival
dc.titlePrognostic value of pet/ct determined sarcopenia inpatients with resected ampullary carcinoma
dc.typearticle
dspace.entity.typePublication
local.avesis.ide93abbbd-bbdf-46dc-a255-02097f60d044
relation.isAuthorOfPublication38325c3e-4399-4724-947c-39953f47fcae
relation.isAuthorOfPublication22952072-1852-47c4-b1ff-669ac16d2ad6
relation.isAuthorOfPublication.latestForDiscovery38325c3e-4399-4724-947c-39953f47fcae

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
9.pdf
Size:
271.29 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs